Get the Stockscreener App
1.25
1.64%
0.03
After Hours:
1.25
Akebia Therapeutics Inc stock is traded at $1.25, with a volume of 1.91M.
It is up +1.64% in the last 24 hours and down -9.49% over the past month.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
See More
Previous Close:
$1.22
Open:
$1.23
24h Volume:
1.91M
Relative Volume:
0.59
Market Cap:
$331.71M
Revenue:
$194.75M
Net Income/Loss:
$-51.26M
P/E Ratio:
-4.4643
EPS:
-0.28
Net Cash Flow:
$-23.38M
1W Performance:
+2.48%
1M Performance:
-9.49%
6M Performance:
-58.94%
1Y Performance:
-31.11%
1-Day Range:
$1.22
$1.28
1-Week Range:
$1.21
$1.51
52-Week Range:
$1.14
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Name
Akebia Therapeutics Inc
Sector
Phone
617-871-2098
Address
245 FIRST STREET, CAMBRIDGE, MA
Compare AKBA vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
1.25 | 323.75M | 194.75M | -51.26M | -23.38M | -0.28 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.98 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.48 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.88 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
490.21 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-04-25 | Resumed | H.C. Wainwright | Buy |
| Apr-28-25 | Initiated | Leerink Partners | Outperform |
| Apr-01-25 | Initiated | Jefferies | Buy |
| Nov-29-23 | Resumed | BTIG Research | Buy |
| Aug-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-31-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-31-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-31-22 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-22 | Downgrade | Needham | Buy → Hold |
| Mar-31-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-14-19 | Reiterated | Needham | Buy |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jul-11-19 | Reiterated | H.C. Wainwright | Buy |
| May-02-19 | Initiated | JP Morgan | Overweight |
| Mar-20-19 | Initiated | Citigroup | Neutral |
| Sep-07-18 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-18 | Reiterated | Needham | Buy |
| Jun-06-18 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-17 | Initiated | Piper Jaffray | Overweight |
| Dec-07-17 | Initiated | BTIG Research | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-10-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-27-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-27-17 | Reiterated | Needham | Buy |
| Dec-27-16 | Reiterated | H.C. Wainwright | Buy |
| Dec-20-16 | Reiterated | JMP Securities | Mkt Outperform |
| Nov-15-16 | Initiated | Aegis Capital | Buy |
| Sep-29-16 | Initiated | Brean Capital | Buy |
| Mar-16-16 | Reiterated | Needham | Buy |
| Jan-21-16 | Initiated | Credit Suisse | Neutral |
View All
Akebia Therapeutics Inc Stock (AKBA) Latest News
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Update - MarketBeat
Citigroup Inc. Has $5.23 Million Position in Akebia Therapeutics, Inc. $AKBA - MarketBeat
Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference - The Globe and Mail
Akebia Therapeutics CEO to speak at Miami Leerink 2026 healthcare forum - Stock Titan
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction - Stocktwits
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), QuidelOrtho (QDEL) and Akebia Therapeutics (AKBA) - The Globe and Mail
Akebia Therapeutics (NASDAQ:AKBA) Lowered to "Strong Sell" Rating by Zacks Research - MarketBeat
Wall Street Zen Downgrades Akebia Therapeutics (NASDAQ:AKBA) to Hold - MarketBeat
Akebia Therapeutics, Inc. (AKBA) Stock Analysis: A Potential 233% Upside in the Healthcare Sector - DirectorsTalk Interviews
Akebia Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q4 2025 Earnings Call Transcript - Insider Monkey
Akebia Therapeutics Inc (AKBA) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges - GuruFocus
Akebia Therapeutics, Inc. posts full year 2025 financial results amid commercial and pipeline expansion - Traders Union
Key facts: Akebia Therapeutics reports 47% revenue rise; Phase 2 trials planned - TradingView
Akebia (AKBA) Q4 2025 Earnings Call Transcript - AOL.com
Akebia Therapeutics (NASDAQ:AKBA) Releases Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Akebia Therapeutics Q4 2025 Earnings Call Insights - Intellectia AI
Akebia Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Akebia Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
AKBA: Vafseo launch drove 50% revenue growth in 2025, with expanding adoption and robust cash reserves - TradingView
Akebia Therapeutics Q4 Earnings Call Highlights - MarketBeat
Akebia Therapeutics Inc (NASDAQ:AKBA) Reports Q4 Revenue Beat and 49% Annual Growth Amid Mixed Market Reaction - ChartMill
Akebia (AKBA) Reports Strong Q4 Revenue and Positive Outlook for Vafseo - GuruFocus
AKEBIA THERAPEUTICS ($AKBA) Releases Q4 2025 Earnings - Quiver Quantitative
Akebia Therapeutics, Inc. Q4 Loss Decreases - Nasdaq
Akebia Therapeutics, Inc. SEC 10-K Report - TradingView
AKBA: Revenue surged 47% to $236.2M in 2025, with Vafseo launch and pipeline expansion offsetting Auryxia LoE - TradingView
[8-K] Akebia Therapeutics, Inc. Reports Material Event | AKBA SEC FilingForm 8-K - Stock Titan
AKBA: Strong 2025 revenue growth and improved margins set the stage for Vafseo-led expansion in 2026 - TradingView
Kidney drug firm Akebia lifts revenue 49% as Vafseo grows - Stock Titan
Analysts Conflicted on These Healthcare Names: Akebia Therapeutics (AKBA), Idexx Laboratories (IDXX) and Arvinas Holding Company (ARVN) - The Globe and Mail
Akebia Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Uncovering Potential: Akebia Therapeutics's Earnings Preview - Benzinga
BTIG Research Has Lowered Expectations for Akebia Therapeutics (NASDAQ:AKBA) Stock Price - MarketBeat
Where Akebia Therapeutics Stands With Analysts - Benzinga
BTIG Maintains Buy Rating on AKBA, Lowers Price Target by 20% | - GuruFocus
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Akebia Therapeutics, Inc. (AKBA): Investor Outlook Reveals 289.83% Potential Upside - DirectorsTalk Interviews
Akebia Therapeutics (AKBA) to Release Quarterly Earnings on Thursday - MarketBeat
Piper Sandler Lowers Akebia Therapeutics (AKBA) PT to $4 as Firm Updates Estimates Following Year-End Reports - Yahoo Finance
Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights - The Globe and Mail
Akebia Therapeutics to Report Fourth Quarter and Full Year - GlobeNewswire
Akebia schedules Feb. 26 webcast on 2025 results, recent moves - Stock Titan
MSN Money - MSN
Quarterly Earnings: How strong is Akebia Therapeutics Inc. stock balance sheetJuly 2025 Closing Moves & Weekly Top Gainers Trade List - mfd.ru
Can Akebia Therapeutics Inc. (AX9) stock sustain margin levels2025 Winners & Losers & Community Consensus Trade Signals - mfd.ru
Is Akebia Therapeutics Inc. a stock for growth or value investorsJuly 2025 Trends & Weekly Watchlist for Consistent Profits - mfd.ru
STATE STREET CORP's Strategic Acquisition of Akebia Therapeutics Inc Shares - GuruFocus
Akebia Therapeutics, Inc. (AKBA) Investor Outlook: A Potential 238% Upside in the Healthcare Sector - DirectorsTalk Interviews
Akebia slumps after Q4 earnings miss - MSN
Akebia Therapeutics Inc Stock (AKBA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.49%
0.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):